40
Participants
Start Date
October 24, 2019
Primary Completion Date
April 30, 2021
Study Completion Date
January 23, 2023
ABX464
All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
Cliniques Universitaires Saint-Luc, Brussels
UZ Gent, Ghent
UZ Leuven, Leuven
ZNA Jan Palfijn, Merksem
Fakultni Tomayerova nemocnice, Prague
Revmatologicky ustav, Prague
CHU de Brest - Hôpital Cavale Blanche, Brest
CHD Vendée, La Roche-sur-Yon
CHU DE MONTPELLIER - Hôpital Lapeyronie, Montpellier
GHR Mulhouse Sud-Alsace, Mulhouse
CHU de Nice - Hôpital Pasteur, Nice
CHR d'Orléans, Orléans
APHP - Hôpital Salpétrière, Paris
CHU de Tours - Hôpital Trousseau, Tours
Complex Medical Centre - Déli Klinika, Budapest
CRU Hungary Ltd., Miskolc
CMed Rehabilitációs és Diagnosztikai Központ, Székesfehérvár
ClinicMed Daniluk, Nowak Sp. J., Bialystok
Pratia MCM, Krakow
Zespół Poradni Specjalistycznych REUMED, Lublin
NZOZ Lecznica MAK-MED S.C., Nadarzyn
Medyczne Centrum Hetmańska, Poznan
National Institute of Geriatrics, Warsaw
RHEUMA MEDICUS Zakład Opieki Zdrowotnej, Warsaw
Lead Sponsor
Abivax S.A.
INDUSTRY